Early testing of an experimental Parkinson’s medicine
Researchers investigate the safety, tolerability and early effects of NCR201 as a possible treatment for Parkinson’s.
Testing a treatment or activity · Study reference: NCT06978920
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (reported actual date)
- 2025-06-06
- Main measurements finished (planned)
- 2026-07-01
- Study finished (planned)
- 2028-12-01
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
- 2026-10-11 — recruiting
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Ages 40 years to 75 years · Does not accept healthy volunteers
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: all
Full study name & original research details
Official study title
A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease
Short title used by the registry
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Original description
Further description from the registry
Conditions reported: Parkinson Disease
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- ClinicalTrials.gov · NCT06978920 ↗ — RECRUITING; checked 2026-10-13
- ClinicalTrials.gov · NCT06978920 ↗ — Recruiting; WHO ICTRP processed 2025-09-08; checked 2026-10-13
- Study type
- Interventional
- Interventions
- Allogeneic dopaminergic neural precursor cell(NCR201)
- Phases
- PHASE1
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Start date reported by registry
- 2025-06-06 (actual)
Registry updated: 2025-08-01 · Status last verified by the registry submitter: 2025-05
Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
No central contact is listed. Check the location contacts or the official registry record.
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
The First Affiliated Hospital of USTC
Hefei, Anhui, China
RecruitingThe First Affiliated Hospital of USTC · 0551-96512 · ahslyyxcb@163.com
Facility not reported
China
Status not reportedThe original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.